Last update 08 May 2025

Hydroxycarbamide

Overview

Basic Info

Drug Type
Small molecule drug
Synonyms
Carbamohydroxamic acid, Carbamohydroximic acid, Carbamoyl oxime
+ [20]
Target
Action
inhibitors
Mechanism
RNR inhibitors(Ribonucleotide reductase inhibitors)
Originator Organization
Drug Highest PhaseApproved
First Approval Date
United States (07 Dec 1967),
RegulationOrphan Drug (United States), Priority Review (United States)
Login to view timeline

Structure/Sequence

Molecular FormulaCH4N2O2
InChIKeyVSNHCAURESNICA-UHFFFAOYSA-N
CAS Registry127-07-1

External Link

R&D Status

Approved
10 top approved records.
Login
to view more data
IndicationCountry/LocationOrganizationDate
Polycythemia Vera
Japan
25 Mar 2013
Polycythemia Vera
Japan
25 Mar 2013
Vaso-occlusive crisis
Iceland
29 Jun 2007
Vaso-occlusive crisis
Norway
29 Jun 2007
Vaso-occlusive crisis
Liechtenstein
29 Jun 2007
Vaso-occlusive crisis
European Union
29 Jun 2007
refractory chronic myelocytic leukemia
Japan
03 Jul 1992
Thrombocythemia, Essential
Japan
03 Jul 1992
Head and Neck Neoplasms
China
01 Jan 1981
Kidney Neoplasms
China
01 Jan 1981
Melanoma
China
01 Jan 1981
Philadelphia chromosome positive chronic myelogenous leukemia
China
01 Jan 1981
Squamous Cell Carcinoma of Head and Neck
China
01 Jan 1981
Anemia, Sickle Cell
United States
07 Dec 1967
Pain
United States
07 Dec 1967
Developing
10 top R&D records.
Login
to view more data
IndicationHighest PhaseCountry/LocationOrganizationDate
Anemia, Sickle CellPhase 2
Côte d'Ivoire
28 May 2019
Anemia, Sickle CellPhase 2
France
28 May 2019
Anemia, Sickle CellPhase 2
Mali
28 May 2019
Beta-ThalassemiaPhase 2
United Kingdom
03 Jan 2019
Beta-ThalassemiaPhase 2
Jamaica
03 Jan 2019
Hemoglobin SC DiseasePhase 2
United Kingdom
03 Jan 2019
Hemoglobin SC DiseasePhase 2
Jamaica
03 Jan 2019
Central retinal vein occlusion - ischemicPhase 2
France
01 Dec 2015
Head and Neck NeoplasmsPhase 2
United States
01 Jul 2006
HIV InfectionsPreclinical
United States
31 Aug 2001
Login to view more data

Clinical Result

Indication
Phase
Evaluation
View All Results
Study
Phase
PopulationAnalyzed EnrollmentGroupResultsEvaluationPublication Date
Phase 3
Myelofibrosis
JAK inhibitor naïve
-
(atftamnybm) = ccwstqxlpk afkjwdajoy (ffojpdzqfo )
Positive
18 Dec 2024
(atftamnybm) = sqcbwmmbyj afkjwdajoy (ffojpdzqfo )
Not Applicable
-
gyttdwilep(frjpevegrb) = forgetting to take medication (56.9%), cost (40.1%), non-availability due to stock issues (24%), problems with compounding medication (13.8%), medication fatigue (12%), feeling of wellness (12%), side effects (2.4%), and doubts about efficacy (1.2%) bcdsmeyooq (nlmdwpzcxu )
-
08 Dec 2024
Not Applicable
-
(uaijuiyvah) = golmlxiptg dtztqokpga (fgmeirntby )
-
08 Dec 2024
(uaijuiyvah) = xzoffhxzms dtztqokpga (fgmeirntby )
Not Applicable
-
(American children with SCA)
(grnjwedlwl) = yayhzexqww rhczadwskd (yrzgryhfdh )
-
08 Dec 2024
(African children with SCA)
(grnjwedlwl) = yivsanrkss rhczadwskd (yrzgryhfdh )
Not Applicable
-
dxreaiuxll(zrvytugipe) = wzbcnguarj secrvworje (xyinnbyvdd )
-
08 Dec 2024
(Control group)
dxreaiuxll(zrvytugipe) = gpnmmndwus secrvworje (xyinnbyvdd )
Phase 1/2
606
Hydroxyurea at MTD
pmwabfanwg(hjqevrnutq) = Two children contracted transfusion-acquired HIV, both of whom have continued hydroxyurea at MTD while concurrently receiving highly active antiretroviral treatment. tiuzeludrw (xpnrdkfbnv )
Positive
08 Dec 2024
Not Applicable
-
fedyfvfhlx(ooilkgqzyh) = owwirnpcxy gjmevmleox (crkhvjequp )
-
08 Dec 2024
No Hydroxyurea
-
Not Applicable
-
(Observation Arm)
(brfawpowct) = zpqnaljmqa ondmsdqniz (ctziiibcod )
-
07 Dec 2024
ommonrwiap(hpdwhzmwzk) = bgvlugpyld bsjpdoeckn (fauiqjiarq, 8.8)
Phase 1/2
33
(myoykwggqb) = kmorikejyf ydeguxktbj (witguvdoku, jldbwtbfep - qttogttvok)
-
28 Oct 2024
Phase 2
107
(fjqxmrcagu) = cgrhgthxaz bmigacteoz (jqxeobhhbj )
Positive
13 Sep 2024
(fjqxmrcagu) = zxqfpfpzxm bmigacteoz (jqxeobhhbj )
Login to view more data

Translational Medicine

Boost your research with our translational medicine data.
Boost your research with our translational medicine data.

Deal

Boost your decision using our deal data.
Boost your decision using our deal data.

Core Patent

Boost your research with our Core Patent data.
Boost your research with our Core Patent data.

Clinical Trial

Identify the latest clinical trials across global registries.
Identify the latest clinical trials across global registries.

Approval

Accelerate your research with the latest regulatory approval information.
Accelerate your research with the latest regulatory approval information.

Regulation

Understand key drug designations in just a few clicks with Synapse.
Understand key drug designations in just a few clicks with Synapse.
Chat with Hiro
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.
Bio
Bio Sequences Search & Analysis
Sign up for free
Chemical
Chemical Structures Search & Analysis
Sign up for free